By otakuyassine3@gmail.com 
Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as $9.66 and last traded at $9.66, with a volume of 464888 shares. The stock had previously closed at $9.56.
Wall Street Analysts Forecast Growth
PSTX has been the subject of a number of research analyst reports. William Blair reaffirmed a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Cantor Fitzgerald downgraded Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Piper Sandler cut Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price target for the company. in a research report on Monday, December 2nd. Finally, BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Poseida Therapeutics has an average rating of “Hold” and an average target price of $9.50.
View Our Latest Report on Poseida Therapeutics
Poseida Therapeutics Trading Up 0.5 %
The business has a 50 day moving average of $6.80 and a 200-day moving average of $4.30. The stock has a market cap of $939.61 million, a PE ratio of -15.25 and a beta of 1.63. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68.
Insider Activity at Poseida Therapeutics
In other news, Chairman Mark J. Gergen sold 30,000 shares of Poseida Therapeutics stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total transaction of $278,100.00. Following the completion of the sale, the chairman now directly owns 651,291 shares in the company, valued at $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.90% of the stock is currently owned by corporate insiders.
Institutional Trading of Poseida Therapeutics
A number of hedge funds have recently bought and sold shares of PSTX. State Street Corp lifted its stake in shares of Poseida Therapeutics by 2.3% during the 3rd quarter. State Street Corp now owns 1,710,565 shares of the company’s stock worth $4,892,000 after purchasing an additional 38,770 shares during the period. Blair William & Co. IL increased its stake in Poseida Therapeutics by 14.1% in the second quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock valued at $3,216,000 after purchasing an additional 136,273 shares during the last quarter. Renaissance Technologies LLC lifted its position in Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after buying an additional 297,500 shares during the period. Dimensional Fund Advisors LP boosted its stake in Poseida Therapeutics by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock worth $1,749,000 after buying an additional 9,672 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Poseida Therapeutics by 3.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 567,063 shares of the company’s stock valued at $1,622,000 after buying an additional 21,255 shares during the period. Institutional investors and hedge funds own 46.87% of the company’s stock.
About Poseida Therapeutics
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
See Also
Receive News & Ratings for Poseida Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Poseida Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.